PL3220892T3 - Postacie dawkowane długo działającego hormonu wzrostu - Google Patents
Postacie dawkowane długo działającego hormonu wzrostuInfo
- Publication number
- PL3220892T3 PL3220892T3 PL15798079T PL15798079T PL3220892T3 PL 3220892 T3 PL3220892 T3 PL 3220892T3 PL 15798079 T PL15798079 T PL 15798079T PL 15798079 T PL15798079 T PL 15798079T PL 3220892 T3 PL3220892 T3 PL 3220892T3
- Authority
- PL
- Poland
- Prior art keywords
- long
- dosage forms
- growth hormone
- acting growth
- hormone dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14194248 | 2014-11-21 | ||
| EP15798079.8A EP3220892B1 (en) | 2014-11-21 | 2015-11-20 | Long-acting growth hormone dosage forms |
| PCT/EP2015/077229 WO2016079302A1 (en) | 2014-11-21 | 2015-11-20 | Long-acting growth hormone dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3220892T3 true PL3220892T3 (pl) | 2022-01-31 |
Family
ID=51945762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15798079T PL3220892T3 (pl) | 2014-11-21 | 2015-11-20 | Postacie dawkowane długo działającego hormonu wzrostu |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12016903B2 (pl) |
| EP (2) | EP3220892B1 (pl) |
| CY (1) | CY1124734T1 (pl) |
| DK (1) | DK3220892T3 (pl) |
| ES (1) | ES2896971T3 (pl) |
| HR (1) | HRP20211734T8 (pl) |
| HU (1) | HUE056849T2 (pl) |
| PL (1) | PL3220892T3 (pl) |
| PT (1) | PT3220892T (pl) |
| SI (1) | SI3220892T1 (pl) |
| WO (1) | WO2016079302A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2279007T3 (en) * | 2008-04-29 | 2016-08-22 | Ascendis Pharma Growth Disorders Div As | Pegylated recombinant relations of human growth hormone |
| DK2512450T3 (en) | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
| US10799563B2 (en) | 2014-11-18 | 2020-10-13 | Ascendis Pharma Endocrinology Division | Polymeric hGH prodrugs |
| PL3220892T3 (pl) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Postacie dawkowane długo działającego hormonu wzrostu |
| US12233113B2 (en) | 2016-02-17 | 2025-02-25 | Genexine, Inc. | Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency |
| WO2018044060A1 (en) * | 2016-08-30 | 2018-03-08 | Genexine,Inc. | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN |
| JOP20190019A1 (ar) * | 2016-08-30 | 2019-02-12 | Genexine Inc | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) |
| SG11202108735QA (en) * | 2019-03-04 | 2021-09-29 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| WO2022197963A1 (en) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Long-acting growth hormone compositions |
| IL305661A (en) * | 2021-03-19 | 2023-11-01 | Pfizer | Methods of administration of polypeptides of growth hormones that have effects over time |
| JP2024541558A (ja) * | 2021-11-26 | 2024-11-08 | ジェネクシン・インコーポレイテッド | Hgh融合タンパク質の高濃度投与剤形 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| IL78930A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Lyophilized emulsion compositions for parenteral administration |
| US5057417A (en) | 1987-06-12 | 1991-10-15 | Genentech, Inc. | Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5179080A (en) | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
| EP0495445A1 (en) | 1991-01-16 | 1992-07-22 | Takeda Chemical Industries, Ltd. | Dual-chamber type syringe |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| IL101007A (en) | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| WO1994010308A1 (en) | 1992-10-23 | 1994-05-11 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| SE501808C2 (sv) | 1993-11-26 | 1995-05-22 | Hans Lundstroem | Anordning vid en box |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| KR100236771B1 (ko) | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
| CA2312975C (en) | 1997-12-17 | 2012-08-21 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| JP4361710B2 (ja) | 2000-04-19 | 2009-11-11 | ジェネンテック・インコーポレーテッド | 徐放製剤 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| HRP20040448A2 (en) | 2001-11-20 | 2006-02-28 | Pharmacia Corporation | Method for detecting cells with numerical chromosomal abnormalities |
| US7144978B2 (en) | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| MXPA05005178A (es) | 2002-11-15 | 2005-07-22 | Hoffmann La Roche | Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). |
| US20040142870A1 (en) | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
| EP1673464A2 (en) | 2003-10-10 | 2006-06-28 | Novo Nordisk A/S | Conjugation of peptides |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| EP1625855A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Polymeric prodrug with a self-immolative linker |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| JP4950022B2 (ja) | 2004-03-23 | 2012-06-13 | コンプレックス バイオシステムズ ゲーエムベーハー | 自壊性リンカーを有する高分子プロドラッグ |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
| EP2284191A3 (en) | 2004-12-22 | 2011-07-20 | Ambrx, Inc. | Process for the preparation of hGH |
| WO2006071840A2 (en) | 2004-12-22 | 2006-07-06 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| US7959600B2 (en) | 2004-12-30 | 2011-06-14 | Byeong S. Chang | Container closure delivery system |
| US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
| JP2008531482A (ja) | 2005-02-10 | 2008-08-14 | ノボ ノルディスク アクティーゼルスカブ | C末端がpeg化された成長ホルモン |
| EP1861125A2 (en) | 2005-03-23 | 2007-12-05 | Nektar Therapeutics Al, Corporation | Conjugates of an hgh moiety and peg derivatives |
| US20100197573A1 (en) | 2005-06-15 | 2010-08-05 | Novo Nordisk Health Care Ag | Transglutaminase Mediated Conjugation of Growth Hormone |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| WO2007025988A2 (en) | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
| KR20150001844A (ko) | 2006-01-24 | 2015-01-06 | 넥스바이오, 인코퍼레이티드 | 고분자 미소 구체들의 조제를 위한 기술 |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2008148839A2 (en) | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
| HRP20110368T1 (hr) | 2007-06-21 | 2011-06-30 | Technische Universitt Mnchen | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro |
| CN101980725B (zh) | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
| EP2113256A1 (en) | 2008-04-29 | 2009-11-04 | Ascendis Pharma AS | PEGylated rhGH compounds |
| DK2279007T3 (en) | 2008-04-29 | 2016-08-22 | Ascendis Pharma Growth Disorders Div As | Pegylated recombinant relations of human growth hormone |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| JP2012519666A (ja) | 2009-03-05 | 2012-08-30 | アセンディス ファーマ エーエス | インターフェロンアルファ担体プロドラッグ |
| WO2011003234A1 (zh) | 2009-07-08 | 2011-01-13 | 深圳市掌网立体时代视讯技术有限公司 | 光学立体放映装置、系统及方法 |
| US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| ES2833035T3 (es) | 2009-07-31 | 2021-06-14 | Ascendis Pharma As | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol |
| DK2512450T3 (en) | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
| EP3372617B1 (en) | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| CN104955472A (zh) | 2012-10-17 | 2015-09-30 | 诺和诺德保健股份有限公司 | 用于生长激素递送的脂肪酸酰化的氨基酸 |
| US10799563B2 (en) | 2014-11-18 | 2020-10-13 | Ascendis Pharma Endocrinology Division | Polymeric hGH prodrugs |
| PL3220892T3 (pl) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Postacie dawkowane długo działającego hormonu wzrostu |
| WO2016109823A1 (en) | 2015-01-02 | 2016-07-07 | Amunix Operation Inc. | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
| SG11202108735QA (en) | 2019-03-04 | 2021-09-29 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
-
2015
- 2015-11-20 PL PL15798079T patent/PL3220892T3/pl unknown
- 2015-11-20 WO PCT/EP2015/077229 patent/WO2016079302A1/en not_active Ceased
- 2015-11-20 HU HUE15798079A patent/HUE056849T2/hu unknown
- 2015-11-20 DK DK15798079.8T patent/DK3220892T3/da active
- 2015-11-20 ES ES15798079T patent/ES2896971T3/es active Active
- 2015-11-20 EP EP15798079.8A patent/EP3220892B1/en active Active
- 2015-11-20 SI SI201531740T patent/SI3220892T1/sl unknown
- 2015-11-20 HR HRP20211734TT patent/HRP20211734T8/hr unknown
- 2015-11-20 EP EP21201573.9A patent/EP3988083B1/en active Active
- 2015-11-20 PT PT157980798T patent/PT3220892T/pt unknown
- 2015-11-20 US US15/528,350 patent/US12016903B2/en active Active
-
2021
- 2021-11-18 CY CY20211100999T patent/CY1124734T1/el unknown
-
2024
- 2024-05-24 US US18/674,686 patent/US20240366730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3988083B1 (en) | 2026-03-11 |
| HRP20211734T8 (hr) | 2022-03-04 |
| US20240366730A1 (en) | 2024-11-07 |
| US20170312342A1 (en) | 2017-11-02 |
| US12016903B2 (en) | 2024-06-25 |
| EP3988083A1 (en) | 2022-04-27 |
| EP3220892B1 (en) | 2021-10-13 |
| HK1244227A1 (zh) | 2018-08-03 |
| SI3220892T1 (sl) | 2022-01-31 |
| PT3220892T (pt) | 2021-11-05 |
| ES2896971T3 (es) | 2022-02-28 |
| EP3220892A1 (en) | 2017-09-27 |
| DK3220892T3 (da) | 2021-11-08 |
| HRP20211734T1 (hr) | 2022-02-18 |
| WO2016079302A1 (en) | 2016-05-26 |
| HUE056849T2 (hu) | 2022-03-28 |
| CY1124734T1 (el) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252708A0 (en) | Immediate-release granulated dosage forms prevent abuse | |
| PL3220892T3 (pl) | Postacie dawkowane długo działającego hormonu wzrostu | |
| GB201407896D0 (en) | Insulin dosage proposal system | |
| GB201509443D0 (en) | Seed preparation | |
| GB201416281D0 (en) | Vegetation catergorisation | |
| SG11201702298VA (en) | Pharmaceutical preparation | |
| IL251413A0 (en) | Composition of injectable buprenorphine | |
| GB201612894D0 (en) | Bird feeder | |
| ZA201608085B (en) | Grout delivery | |
| TWI561461B (en) | Epitaxial structure | |
| SG11201609037UA (en) | Ground improvement method | |
| PL3143095T3 (pl) | Mieszanina soli | |
| TWM488998U (en) | Syringe | |
| PT2910223T (pt) | Emplastro com dispensador de medicação | |
| SG11201704819WA (en) | Syringe | |
| IL249374A0 (en) | Pharmaceutical administration forms | |
| GB201411038D0 (en) | Bird feeder | |
| IL255667A (en) | Plant hormone application | |
| GB2525899B (en) | Bird Feeder | |
| GB201413196D0 (en) | Bale Spike | |
| TWM489981U (en) | Warm-keeping structure | |
| TWM489515U (en) | Warm-keeping scarf structure | |
| HU4548U (en) | High flowerbed construction | |
| GB201508787D0 (en) | Pharmaceutically active compounds | |
| GB201415811D0 (en) | Solid dosage form production |